FDA Advisory Committee Unanimously Approves Eli Lilly's Alzheimer's Drug as Safe and Effective from 11 18 inc Watch Video
Preview(s): Play Video: (Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
Your browser does not support playing the video.Please download the video!
⏲ Duration: 0:29 👁 View: 170K times ✓ Published: 12-Jun-2024
Description: An FDA advisory committee voted unanimously that Eli Lilly's Alzheimer's drug donanemab is safe and effective for treating early-stage Alzheimer's disease. The drug works by helping the body remove amyloid plaque buildup in the brain, that are a hallmark of Alzheimer's disease. In clinical trials, the drug reduced the risk of Alzheimer's progression by 37% over 18 months compared to a placebo. Three patients died from microhemorrhages while on donanemab. The advisory committee voted that donanemab's benefits outweighed its risks for patients enrolled in the clinical trials.